SEEL - Seelos Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8700
-0.0500 (-1.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.9200
Open2.9000
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range2.7953 - 2.9495
52 Week Range1.3200 - 17.4000
Volume652,876
Avg. Volume4,894,527
Market Cap58.014M
Beta (3Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-0.7190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC

    NEW YORK, April 16, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will present and host 1x1 and small.

  • ACCESSWIRE21 days ago

    Two Months into a Reverse Merger, Where Does Seelos Therapeutics Stand Now?

    NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Benzinga25 days ago

    Why Seelos Therapeutics Shares Are Surging Out Of The Gate

    Thinly traded nanocap biotech Seelos Therapeutics Inc (NASDAQ: SEEL) is trading sharply higher on over three times its average volume. Seelos, which develops therapies for central nervous system disorders and other rare conditions, issued an update after the close Thursday on its pipeline development as well as corporate highlights. Since the completion of the reverse merger Jan. 24, Seelos has acquired two candidates: SLS-005 targeting orphan diseases of the CNS; and SLS-007 targeting alpha-synuclein aggregates in Parkinson's disease.

  • GlobeNewswire25 days ago

    Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company provided an update on recent pipeline developments and corporate highlights. “Seelos successfully transitioned into a publicly traded company on Nasdaq by completing its reverse merger with Apricus BioSciences, Inc. on January 24, 2019,” said Raj Mehra, PhD, Chairman, Founder, and CEO of Seelos.

  • ACCESSWIRE27 days ago

    Four Healthcare Stocks Picking Up Speed on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.

  • ACCESSWIRElast month

    A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?

    The FDA recently took a big step towards blessing the emerging field of brain-computer interfacing technology, which has broad application in prosthetics and even enhancing the human brain. Visionaries like Elon Musk are betting on the latter happening quickly, and startups like his are designing software and hardware to capitalize on new technology breakthroughs. This field of neurology, sometimes known as neuromodulation, has only recently come into the pubic markets spotlight with companies like electroCore, Inc. (ECOR) and Nuvectra (NVTR) going public with technology that can assuage pain through electric stimulation of the nervous system.

  • MarketWatch2 months ago

    Shares of Seelos Therapeutics up 80% Friday morning

    Shares of Seelos Therapeutics were up 80% on Friday morning as investors continued to react positively to Tuesday's announcement that the small biotech had exclusively in-licensed a family of peptide inhibitors from The Regents of the University of California. The peptide inhibitors, which were developed by a research team at the University of California, Los Angeles, target the aggregation of alpha-synuclein. Alpha-nuclein is a major component of Lewy bodies, protein clumps that are a hallmark of Parkinson's Disease. Seelos said it plans to study the inhibitors as a potential treatment approach in Parkinson's and will look at other diseases down the line. Under the terms of the agreement, Seelos made an upfront payment to The UC Regents and UCLA. The company also agreed to pay future royalties upon commercialization. Shares of Seelos have fallen 65% in the year to date, while the S&P 500 has gained 4.4%.

  • ACCESSWIRE2 months ago

    Four Healthcare Stocks Looking To Close Out a Strong Week on Friday

    CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / The healthcare stock market has seen impressive gains in the first few months of 2019 as we've seen several major shifts to the healthcare system in the U.S. In the last few years, by virtue of technological advancements and cultural changes, the healthcare industry has become increasingly more patient-centered. Until recently, patients were less vocal about their needs and the privacy of their medical records, but, just like consumers advocating for better customer experience, so, too, are patients expecting quality from their care providers. If companies in the healthcare sector continue to rise to the growing challenges presented by new diseases, patient expectations, and the ever-changing political climate, investors looking for potential opportunities could benefit from keeping healthcare on their radar.

  • GlobeNewswire2 months ago

    Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today that it has acquired an exclusive license to intellectual property owned by The Regents of the University of California (The UC Regents) pertaining to a technology that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). Seelos plans to study this initial approach in Parkinson's disease (PD) and will further evaluate the potential clinical approach in other disorders affecting the central nervous system (CNS).

  • ACCESSWIRE2 months ago

    Four Tech Stocks To Watch on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The tech stock market has been a hotbed of exciting conversation during the last few months as a result of word spreading about tech companies taking innovative approaches to create new technologies for the betterment of humankind. Stemming from the belief that consumers deserve to live life to the best of their ability, these tech companies have pioneered technological advancements in the areas of augmented reality, cloud computing, and countless others. ParcelPal Technology Inc (PTNYF) (PKG), Seelos Therapeutics Inc (SEEL), Renren Inc (RENN), and Ohr Pharmaceutical Inc (OHRP) represent 4 tech stocks on the rise on Wednesday.

  • GlobeNewswire2 months ago

    Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annual ROTH Conference

    NEW YORK, March 06, 2019 -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will webcast their presentation at.

  • GlobeNewswire2 months ago

    Seelos Therapeutics to Present at the 39th Annual Cowen Health Care Conference

    NEW YORK, March 01, 2019 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that they will participate in the 39th Annual.

  • GlobeNewswire2 months ago

    Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

    Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company, announced today a definitive agreement with Bioblast Pharma Ltd., (ORPN), whereby Seelos acquired all development and commercial rights to Bioblast’s proprietary trehalose 90 mg/mL IV (Trehalose) solution as well as the existing inventory of the drug which should be sufficient to fulfill its current research needs. Trehalose, which is currently an investigational molecule, has been studied in prior phase 2 clinical studies in over 70 patients with two rare diseases and demonstrated a favorable safety profile and promising efficacy signal.